- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 3/00 - Drugs for disorders of the metabolism
Patent holdings for IPC class A61P 3/00
Total number of patents in this class: 7171
10-year publication summary
|
146
|
168
|
288
|
345
|
357
|
431
|
434
|
478
|
487
|
437
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Mondobiotech Laboratories AG | 311 |
282 |
| F. Hoffmann-La Roche AG | 7933 |
61 |
| Takeda Pharmaceutical Company Limited | 2717 |
56 |
| Janssen Pharmaceutica N.V. | 3351 |
53 |
| Boehringer Ingelheim International GmbH | 4635 |
52 |
| Bristol-myers Squibb Company | 4820 |
51 |
| Amicus Therapeutics, Inc. | 353 |
47 |
| Novartis AG | 10623 |
46 |
| The Trustees of the University of Pennsylvania | 4384 |
43 |
| Pfizer Inc. | 3401 |
42 |
| Société des Produits Nestlé S.A. | 9886 |
41 |
| Modernatx, Inc. | 1298 |
40 |
| Regeneron Pharmaceuticals, Inc. | 4444 |
39 |
| Eli Lilly and Company | 3925 |
36 |
| The Regents of the University of California | 20289 |
35 |
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 3210 |
33 |
| Amgen Inc. | 4258 |
32 |
| Genzyme Corporation | 1310 |
32 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 842 |
32 |
| sanofi-aventis | 346 |
30 |
| Other owners | 6088 |